News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
UK’s NICE Says Bristol-Myers Squibb Company’s Orencia Not Recommended for Rheumatoid Arthritis
April 24, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - The UK's healthcare spending watchdog NICE has announced that it does not recommend Bristol-Myers Squibb Co's abatacept-based Orencia as a treatment option for people with rheumatoid arthritis, its indicated use.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Bristol Myers Squibb Company
MORE ON THIS TOPIC
RNA editing
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
November 13, 2025
·
3 min read
·
Annalee Armstrong
Obesity
Zealand Freezes Mid-Stage Obesity Asset to Focus on More Differentiated Drugs
November 13, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
November 13, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Five Trends That Got Everyone Talking in Pharma and Biotech This Year
November 12, 2025
·
5 min read
·
Jennifer Smith-Parker
